Trial
NCT04660045
Early Intervention With Acalabrutinib in Patients With High Risk CLL
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
AstraZeneca
Condition
Chronic Lymphocytic Leukemia
Intervention
Acalabrutinib
Why stopped
Company supplying drug/funding ceased support.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-05